ID   MOLP-6
AC   CVCL_9984
DR   CGH-DB; 35-1
DR   CGH-DB; 9148-4
DR   Wikidata; Q54906338
RX   PubMed=10937346;
RX   PubMed=15215163;
CC   Population: Japanese.
CC   Characteristics: Requires bone marrow stromal cells for optimal growth.
CC   Doubling time: 48 hours (PubMed=10937346).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9985 ! MOLP-7
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 12
//
RX   PubMed=10937346;
RA   Harashima A., Matsuo Y., Nishizaki C., Kozuka T., Fukuda S.,
RA   Sezaki T., Orita K.;
RT   "Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6
RT   and MOLP-7 derived from a patient with multiple myeloma.";
RL   Hum. Cell 13:43-54(2000).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//